| Literature DB >> 35604172 |
Raquel Martínez-López1,2, Maria Luisa Hernáez3, Esther Redondo1, Guillermo Calvo1, Sonja Radau4, Mercedes Pardo5, Concha Gil1,2,3, Lucía Monteoliva1,2.
Abstract
Candida albicans is the principal causative agent of lethal fungal infections, predominantly in immunocompromised hosts. Extracellular vesicles (EVs) have been described as crucial in the interaction of microorganisms with their host. Since the yeast-to-hypha transition is an important virulence trait with great impact in invasive candidiasis (IC), we have addressed the characterization of EVs secreted by hyphal cells (HEVs) from C. albicans, comparing them to yeast EVs (YEVs). YEVs comprised a larger population of bigger EVs with mainly cell wall proteins, while HEVs were smaller, in general, and had a much higher protein diversity. YEVs were able to rescue the sensitivity of a cell wall mutant against calcofluor white, presumably due to the larger amount of cell wall proteins they contained. On the other hand, HEVs also contained many cytoplasmic proteins related to protein metabolism and intracellular protein transport and the endosomal sorting complexes required for transport (ESCRT) pathway related to exosome biogenesis, pointing to an intracellular origin of HEVs. Interestingly, an active 20S proteasome complex was secreted exclusively in HEVs. Moreover, HEVs contained a greater number of virulence-related proteins. As for their immunogenic role, both types of EV presented immune reactivity with human sera from patients suffering invasive candidiasis; however, under our conditions, only HEVs showed a cytotoxic effect on human macrophages and could elicit the release of tumor necrosis factor alpha (TNF-α) by these macrophages. IMPORTANCE This first analysis of HEVs of C. albicans has shown clear differences between them and the YEVs of C. albicans, showing their relevance and possible use in the discovery of new diagnostic markers and treatment targets against C. albicans infections. The data obtained point to different mechanisms of biogenesis of YEVs and HEVs, as well as different involvements in cell biology and host interaction. YEVs played a more relevant role in cell wall maintenance, while HEVs were more closely related to virulence, as they had greater effects on human immune cells. Importantly, an active 20S proteosome complex was described as a fungal-EV cargo. A deeper study of its role and those of many other proteins exclusively detected in HEVs and involved in different relevant biological processes of this fungus could open up interesting new areas of research in the battle against C. albicans.Entities:
Keywords: Candida albicans; cell wall maintenance; exosomes; extracellular vesicles; hyphae; immunogenic; macrophages; proteasome; proteomics; virulence factors; yeast
Mesh:
Substances:
Year: 2022 PMID: 35604172 PMCID: PMC9241596 DOI: 10.1128/spectrum.00698-22
Source DB: PubMed Journal: Microbiol Spectr ISSN: 2165-0497
FIG 1Differences in size and protein diversity between YEVs and HEVs. Size distribution by intensity pattern (DLS) and appearance (TEM) of YEVs (a) and HEVs (b). d.nm, diameter in nm. (c) Venn diagram showing the number of identified proteins that are in common or exclusive to EVs from each cell morphology.
FIG 2Proteins identified in both types of EVs are enriched in cell surface proteins and contribute to rescuing the ecm33Δ phenotype. (a) FunRich categorization of component enrichment of proteins identified in both YEVs and HEVs. The P value for significance is <0.001. (b) Rescue of the calcofluor white (CW) sensitivity exhibited by the ecm33 mutant through the addition of YEVs and HEVs. The growth of the ecm33 mutant was assayed in YPD and in YPD supplemented with 7 μg/mL of cell wall-disturbing agent CW in the absence or presence of 5 μg of either YEVs or HEVs. Error bars show standard deviations.
FIG 3(a) Heat map of all proteins identified in YEVs based on their relative abundances (NSAF) in YEVs and HEVs. (b) Heat map of proteins from (a) described as cell surface related according to the CGD database. Proteins exclusively detected in YEVs show a value of zero for relative abundance in the HEV column.
FIG 4HEVs are enriched in proteins related to protein metabolism, transport, and biosynthetic pathways. FunRich categorization of component (a) and biological process (b) enrichment of proteins identified exclusively in HEVs and not in YEVs. Cellular components and biological processes marked with an asterisk (*) were enriched exclusively in HEVs and not in HWCL. (c) Venn diagram showing the number of identified proteins that are in common or exclusive to HEV and HWCL.
FIG 5Protein-protein interaction network of proteins identified in HEVs using STRING software. Only nodes corresponding to proteins with the highest confidence (0.900) in active interaction sources of cooccurrence, coexpression, experiments, and neighborhood are shown.
List of proteins identified in HEVs and YEVs related to biological processes that are enriched in HEV protein cargo and to virulence
| Biological process | No. of proteins identified: name(s) or ORF(s) | Total no. in: | |||
|---|---|---|---|---|---|
| In both YEVs and HEVs | Exclusively in: | ||||
| YEVs | HEVs | YEVs | HEVs | ||
| Cellular processes | |||||
| Proteasome | 2: Pre5 (α6), Orf19.1785 | 31: Scl1 (α1), Pre8 (α2), Pre9 (α3), Pup2 (α5), Prs1/Pre10 (α7), Pre3 (β1), Pup1 (β2), Pup3 (β3), Pre1 (β4), Pre2 (β5), Pre4 (β7), Rpt1, Rpt2, Rpt4, Rpt5, Rpt6, Rpn1, Rpn2, Rpn3, Rpn5, Rpn6, Rpn7, Rpn8, Rpn11, Ubp6, Ubc4, Ecm29, Hsm3, Orf19.2278, Orf19.6604, Pr26 | 33 | ||
| Translation factors (initiation, elongation, and release) | 4: Ded81, Anb1, Tif, Tef2 | 13: Fun12, Sui2, Eif4e, Tif11, Tif5, Nip1, Prt1, Sui1, Sui3, Gcd2, Gcd11, Ria1, | 4 | 17 | |
| tRNA synthetases and ligases | 1: Orf19.6701 | 14: Grs, Dps1-1, Gln4, Mes1, Orf19.4931, Wrs1, Vas1, Tys1, Ths1, Hts1, Mes1, Frs1, Frs2, Gus1 | 1 | 15 | |
| Ribosomal proteins | 4: Asc1, Rpl12, Rpl14, Rpl10a | 68: Rps18, Rps3, Rpl23a, Rpl6, Rps14b, Rpl3, Rpl20b, Rps8a, Rps26a, Rps27, Rpl10, Rps15, Rps5, Rps6a, Rps9b, Rpp0, Rps20, Rpl9b, Rpl4b, Rps22a, Rpl11, Rpl16a, Rpl19a, Rpl28, Rps24, Rpl38, Rpl24a, Rps17b, Rpl21a, Rps25b, Rps7a, Rpl15a, Rpl18, Rpl17b, Rpl13, Orf19.3341, Rps23a, Rpl5, Rpl7, Rps16a, Rps1, Orf19.4149.1, Rps13, Rpl27a, Orf19.2478.1, Rpl30, Rpl39, Rpl32, Rps19a, Orf19.3572.3, Orf19.3690.2, Rpl25, Rpl2, Rpl43a, Rpl35, Rps12, Rps21b, Rpl42, Rpp2a, Rps28b, Rpp2b, Rpl37b, Orf19.6220.4, Orf19.828, Orf19.512, Orf19.3778, Orf19.3559, Orf19.5698 | 4 | 72 | |
| Purine and pyrimidine biosynthesis | 4: Ade13, Ade17, Ade 6, Ado1 | 17: Ade1, Ade2, Ade4, Ade5, Ade12, Imh3, Gua1, Cpa1, Cpa2, Ura1, Ura2, Ura3, Ura4, Ura5, Ura6, Ura7, Prs1 | 4 | 21 | |
| Amino acid biosynthesis | 20: Hom6, Met6, Met15, Sah1, Sam2, Shm2, Cys3, Idp1, Idp2, Car2, His7, Asn1, Aro4, Aro8, Leu2, His1, Ser33, Arg1, Lys9, Ilv5 | 1: Hom2 | 46: Aro3, Aro9, Pro1, Pro2, Pro3, Lys1, Lys2, Lys4, Lys12, Lys21, Lys22, Arg3, Arg4, Arg5,6, Arg8, Trp2, Trp3, Trp4, Trp5 Cys4, Ser1, Ser2, His4, His5, His7, Tyr1, Prs1, Orf19.6306, Met2, Met3, Met10, Met13, Met14, Met16, Met18, Met13, Ilv1, Ilv2, Ilv3, Ilv6, Hom3, Sam51, Shm1, Leu1, Leu4, Leu42 | 21 | 66 |
| Ergosterol biosynthesis | 3: Erg10, Erg13, Erg20 | 2: Fmp45, Gcy1 | 11: Erg1, Erg3, Erg4, Erg5, Erg6, Erg9, Erg11, Ncp1, Erg26, Erg27, Hmg1 | 5 | 14 |
| Required for resistance to toxic ergosterol analog | 5: Car2, Dag7, Orf19.2047, Mnn23, Ypt31 | 1: Sap3 | 4: Amo2, Apl2, Nat2, Vid27 | 5 | 9 |
| Induced by azole treatment or linked to azole resistance | 52: Ach1, Aco1, Acs1, Adh1, Ado1, Ahp1, Ald5, Atp1, Cat1, Cht2, Dag7, Dak2, Ecm33, Eng1, Erg10, Ero1, Fba1, Fdh1, Fet34, Fma1, Gdh3, Glk1, Glx3, Gpm1, Grp2, Hhf1, Hsp70, Hsp90, Hxk2, Mcr1, Mid1, Mp65, Msi3, Orf19.1765, Orf19.1766, Orf19.7306, Pbr1, Pck1, Pdc11, Pet9, Pga52, Phr2, Plb3, Png2, Prx1, Pyc2, Rbt1, Rhd3, Sah1, Sur7, Tos1, Xyl2 | 7: Ade17, Als2, Bat22, Hom2, Orf19.4211, Pir1, Plb1 | 75: Asm3, Cdc3, Cka1, Cka2, Cmp1, Csh1, Cyb5, Ece1, Ecm331, Ena21, Erg11, Erg3, Erg4, Erg6, Erg9, Fas1, Fas2, Frp3, Fum12, Gal1, Gal10, Gal7, Glc3, Gph1, Gst2, Hgt7, Hsp21, Hym1, Hyr1, Ifd6, Ife2, Lsc1, Lys21, Lys22, Met13, Met3, Mir1, Mis11, Ncp1, Ole1, Op4, Orf19.1239, Orf19.2269, Orf19.2286, Orf19.2452, Orf19.2473, Orf19.3475, Orf19.3932, Orf19.4476, Orf19.6553, Orf19.6554, Orf19.7310, Orf19.7459, Orf19.851, Pda1, Pdb1, Pdr16, Pfk1, Pfk2, Plb5, Pma1, Por1, Rct1, Rnr21, Rpl35, Scs7, Sds24, Snf1, Snz1, Svf1, Tub2, Ucf1, Vma8, Zpr1 | 59 | 127 |
| Virulence related | |||||
| Phospholipases | 3: Plb4.5, Plb2, Plb3 | 1: Plb1 | 2: Plc2, Plb5 | 4 | 5 |
| Sap proteins | 4: Sap5, Sap7, Sap 9, Sap10. | 1: Sap3 | 4: Sap2, Sap4, Sap6, Sap8 | 6 | 8 |
| Als proteins | 1: Als3 | 1: Als2 | 1: Als1 | 2 | 2 |
| Proteins with a role in virulence according to CGD | 12: Mnt1, Phr1, Het1, BglII, Rbt4, Rbt1, Asc1, Cdc42, Mnt2, Hex1, Kex2, Cat1 | 0 | 56: Hsp104, Nag1, Cdc3, Fas2, Vps21, Hxk1, Srv2, Rsr1, Mts1, Ras1, Tps1, Tps2, Alo1, Rvs161, Cdc10, Dac1, Arp2, Lap3, Kre5, Hsp21, Icl1, Ade5, Yhb1, Ade2, Gna1, Tpk2, Ftr1, Ssd1, Cka2, Mkc1, Orf19.3045, Ptc2, Met2, Nce103, Vtc4, Cmp1, Erg3, Nag6, Ura3, Slk19, Vps4, Orf19.3175, Och1, Ypt72, Csh3, Cek1, Pmt1, Pmt4, Bem1, Tcc1, Ssn6, Spf1, Pde2, Cla4, Mlt1, Spa2 | 12 | 68 |
ORF, open reading frame.
The protein is a translation elongation factor.
The protein is a translation release factor.
The protein is a tRNA synthetase or ligase.
FIG 6An active proteasome complex is only identified within HEVs’ protein cargo. (a) Schematic representation of the proteasome complex showing all the proteins from the 20S core particle and 19S regulatory particle. Proteins identified in HEVs are marked in green. *, proteins only identified in the proteasome complex from one-dimensional (1-D) blue native PAGE (BN-PAGE). α6 subunit, also identified in YEVs, is surrounded by a red line. (b) Separation of YEV and HEV complexes by 1-D BN-PAGE. The band corresponding to the proteasome complex is indicated by an arrow. (c) Validation of the chymotrypsin-protease activity of the proteasome through a fluorometric assay (in relative fluorescence units [RFU]). The chymotrypsin-protease activity of the proteasome from 100 μg of cytoplasmic extract was evaluated as a positive control. A significant change is indicated as follows: ****, P < 0.0001 (unpaired t test). Error bars show standard deviations.
List of proteins identified in HEVs and related to pathways and structures involved in vesicular transport
Categorization is according to the CGD. Conditional coloring is applied according to the relative abundance of the protein (NSAF) within HEVs (red is the most abundant and green is the least). If the protein has also been identified in YEVs, its relative abundance within YEVs is also shown, while if such a protein has not been identified in YEVs, the YEV column is blank.
FIG 7Differences in the immune response against YEVs and HEVs. (a) SDS-PAGE Coomassie-blue stained gel and Western blot showing the immunoreactive patterns of YEV and HEV protein extracts to sera from patients suffering invasive candidiasis. (b) Percentage of cytotoxicity produced by either HEVs or YEVs to TPH1 macrophages. (c) TNF-α release from TPH1-activated macrophages (mØ) incubated for 8 or 24 h with 5 μg of YEVs or HEVs. Negative and positive controls (with the addition of PBS and LPS, respectively) were also evaluated. A significant change is indicated as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001 (unpaired t test). Error bars show standard deviations.
FIG 8Schematic representation of the main differences observed between HEVs and YEVs regarding their protein cargoes and interactions with THP1 macrophages. An enlarged view of an HEV and a YEV showing the main component-related protein enrichment of each type of EV is also presented.